This is the first pre-qualification for a generic version of Pfizer s Covid-19 oral antiviral drug Paxlovid , which the WHO called, the best therapeutic choice for high-risk patients to date.WHO
This is the first pre-qualification for a generic version of Pfizer s Covid-19 oral antiviral drug Paxlovid , which the WHO called, the best therapeutic choice for high-risk patients to date.WHO
Leading pharmaceutical company Hetero on Monday announced that it has received the World Health Organization Prequalification of Medicines Programme (WHO PQ) approval for its generic version of Covid-19 oral antiviral treatment candidate .